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Abstract: A dendritic cell-based, Type 1 Helper T cell (Th1)-polarizing anti-Human Epidermal Growth
Factor Receptor-2 (HER-2) vaccine supplied in the neoadjuvant setting eliminates disease in up to 30%
of recipients with HER-2-positive (HER-2pos) ductal carcinoma in situ (DCIS). We hypothesized that
drugs with low toxicity profiles that target signaling pathways critical for oncogenesis may work in
conjunction with vaccine-induced immune effector mechanisms to improve efficacy while minimizing
side effects. In this study, a panel of four phenotypically diverse human breast cancer lines were
exposed in vitro to the combination of Th1 cytokines Interferon-gamma (IFN-γ) and Tumor Necrosis
Factor-alpha (TNF-α) and lipophilic statins. This combination was shown to potentiate multiple
markers of apoptotic cell death. The combination of statin drugs and Th1 cytokines minimized
membrane K-Ras localization while maximizing levels in the cytoplasm, suggesting a possible means
by which cytokines and statin drugs might cooperate to maximize cell death. A combined therapy was
also tested in vivo through an orthotopic murine model using the neu-transgenic TUBO mammary
carcinoma line. We showed that the combination of HER-2 peptide-pulsed dendritic cell (DC)-based
immunotherapy and simvastatin, but not single agents, significantly suppressed tumor growth.
Consistent with a Th1 cytokine-dependent mechanism, parenterally administered recombinant IFN-γ
could substitute for DC-based immunotherapy, likewise inhibiting tumor growth when combined
with simvastatin. These studies show that statin drugs can amplify a DC-induced effector mechanism
to improve anti-tumor activity.
Keywords: statin; breast cancer; cytokine; apoptosis; Ras; vaccine
1. Introduction
The Human Epidermal Growth Factor Receptor-2 (HER-2) oncodriver is associated with a poorer
prognosis for breast cancer [1,2]. However, the use of HER-2 peptide-loaded IL-12-secreting dendritic
cells (DC) for neoadjuvant vaccination against early breast cancer (DCIS; ductal carcinoma in situ)
has led to complete pathological responses (pCR; i.e., no remaining disease) in up to 30% of immunized
subjects [3–6]. The vaccine elicited strong Type 1 helper T cell (Th1) immunity, with high levels of CD4
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T cells often observed infiltrating areas of disease post-vaccination, and strongly suppressed HER-2
expression in many patients with residual disease [3,4]. Predominance of peritumoral CD4 T cells
suggested Th1 cytokines may be responsible for some of the vaccine effect. Indeed, combinations of
IFN-γ and TNF-α typically induced high levels of senescence and apoptosis in multiple HER-2-positive
(HER-2pos) breast and other cancer lines in vitro, with concomitant suppression of HER-family
expression, thereby mimicking in vivo observations following DC vaccination [7,8].
In previous vaccine trials, we observed that the majority of pCRs had estrogen receptor
(ER)-negative tumors, while ER-positive patients only seldom (5%) displayed pCR [4,5]. This was
a concern because nearly 50% of HER-2pos breast cancers also overexpress hormone receptors [9],
potentially limiting vaccine utility. We and others propose that combinatorial therapies will be
a highly fruitful avenue for improving outcomes for breast cancer [10,11]. Such a strategy, combining
anti-estrogen drugs in vitro with Th1 cytokines, greatly enhanced killing of ER-positive breast cancer
lines, an approach which was subsequently validated in a clinical trial where anti-estrogen therapy plus
vaccination boosted pCR rates of ER-positive subjects from 5% to 30% [6]. By continuing this successful
strategy, we should be able to rapidly screen additional candidate drugs in vitro for cooperative effects
with Th1 cytokines, and then swiftly translate these findings into pilot clinical studies to determine
whether these additions lead to improvements in vaccine efficacy.
Statin drugs are used to treat hypercholesterolemia and taken daily by millions of people
with few adverse side effects [12]. In vitro and in vivo evidence suggests that statins may also
possess unanticipated anti-cancer properties [13–15]. Statins may exert pleiotropic anti-tumor effects
by inhibiting the cholesterol biosynthetic (mevalonate) pathway, responsible for both cholesterol
production and the generation of lipids that facilitate association of certain molecules to the cell
membrane [13,16]. For example, Ras oncogene products rely on the mevalonate pathway for
hydrophobic prenyl groups enabling its association with the cytoplasmic face of the plasma membrane,
without which Ras cannot signal [17,18]. Simvastatin and fluvastatin are potent lipophilic statin drugs
that induce apoptosis in human breast cancer cell lines [19–21]. Targeting additional intracellular
signaling pathways like Ras, through the use of lipophilic statins, could theoretically enhance tumor
cell death in combination with therapeutic vaccination in people. Here, we report that Th1 cytokines
work in conjunction with statin drugs to potentiate tumor cell death via apoptosis with the unexpected
effect of localizing Ras away from the membrane and into the cytoplasm. Furthermore, statin drugs
combined with a DC-based immunotherapy retards tumor progression in a murine model of HER-2pos
breast cancer. These findings suggest that statin drugs can act as a kind of “biochemical adjuvant”
to enhance the efficacy of anti-cancer immunotherapies that work in part through Th1 immunity,
or the effectors thereof.
2. Materials and Methods
2.1. Activation of Simvastatin
Activation of simvastatin, which opens the lactone ring, was performed as previously described
by others [22]. Briefly, 8 mg of simvastatin was dissolved in 0.2 mL of 100% ethanol (Spectrum,
New Brunswick, NJ, USA) and then 0.3 mL of 0.1 M NaOH (Sigma-Aldrich, St. Louis, MO, USA)
was added. The solution was heated at 50 ◦C for 2 h then neutralized with HCl (Sigma-Aldrich,
St. Louis, MO, USA) to pH 7.2. The resulting solution was brought to 1 mL with distilled water,
and aliquots were stored at −80 ◦C until use.
2.2. Cell Culture
Human breast cancer cell lines SK-BR-3 (RRID: CVCL_0033) and MDA-MB-468 (RRID: CVCL_0419)
were obtained from American Type Culture Collection (Rockwell, MA, USA). The HCC1419 (RRID:
CVCL_1251) cell line was a gift from Dr. Brian Czerniecki (H. Lee Moffitt Cancer Center),
and the MDA-MB-231 (RRID: CVCL_0062) cell line was a gift from Dr. Gail Fraizer (Kent State
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University). Cell line identity was confirmed by Short Tandem Repeat (STR) profiling. All cell lines
were cultured and maintained as described previously [23].
2.3. Alamar Blue Assay
Cells were seeded in 96-well culture plates (8 × 103 cells/50 µL per well) and incubated overnight.
The next day, cells were treated with Th1 cytokines (ranging from 10 to 20 ng/mL each recombinant
human IFN-γ and TNF-α) (Peprotech, Rocky Hill, NJ, USA), or left untreated (controls). Additional
treated and untreated groups received statin drugs at concentrations ranging from 0 to 100 µM
(Selleckchem, Houston, TX, USA). Cells were incubated for 72 h post-treatment, then treated with
Alamar Blue dye and assayed as previously described [23].
2.4. Trypan Blue Assay
Cells were harvested 72 h post-treatment with Th1 cytokines and statin drugs, stained with Trypan
Blue dye, and assessed as described previously [23].
2.5. Mitochondrial Membrane Potential Assessment (TMRE)
At 24, 48, and 72 h post-treatment with Th1 cytokines and statin drugs, cells were stained with
tetramethylrhodamine ethyl ester (TMRE), harvested, and assessed as described previously [23].
2.6. Fluorescein Isothiocyanate (FITC)-Annexin V and Propidium Iodide (PI) Staining
Approximately 48 h post-treatment, cells were harvested and resuspended in 50 µL of 1× Binding
Buffer (Invitrogen by Thermo Fisher Scientific, Eugene, OR, USA), and 3 µL of FITC-Annexin V
(Invitrogen) was added per sample. Samples were incubated for an additional 15 min. Immediately
prior to flow cytometry analysis, 0.5 µL of 0.1 mg/mL PI (Invitrogen) was added to each sample.
For each sample, 2500 intact/single-cell events were analyzed on the Amnis Flowsight using the 488
nm excitation laser.
2.7. CellEvent™ Caspase Activation Assay
Approximately 48 h post-treatment, 1 µL of Caspase 3/7 Green Detection Reagent (Invitrogen)
per 1 mL of media was added to each sample, samples were incubated for an additional 30 min.
Cells were then harvested and resuspended in 1X Phosphate-Buffered Saline (PBS) (Corning Cellgro,
Manassas, VA, USA). For each sample, 5000 intact/single-cell events were analyzed on the Amnis
Flowsight using the 488 nm excitation laser, and the shift in fluorescence of the gated single-cell events
was used to assess cells with active caspases-3/7.
2.8. Western Blotting
Membrane fractionation was conducted using the Mem-PER™ Plus Membrane Protein
Extraction Kit (Cat # 89842, Pierce Biotechnology, Thermo Scientific, Rockford, IL, USA) following
the manufacturer’s recommendations. Both the kit buffers (Permeabilization and Solubilization)
were supplemented with protease inhibitor cocktail (Pierce) and PhosStop phosphatase inhibitor
cocktail (Roche, Mannheim, Germany). Whole-cell lysates were prepared by extracting proteins with
RIPA lysis buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate, and 50 mM Tris pH 8.0) containing protease inhibitor cocktail and PhosStop
phosphatase inhibitor cocktail. Total protein (50 µg) was separated by SDS-polyacrylamide gel
electrophoresis and western blotting/signal detection performed as described previously [23]. Primary
antibodies included K-Ras (Sigma-Aldrich, St. Louis, MO, USA, #WH0003845M1), β-actin (Millipore,
#MAB1501), MAP-ERK 12 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, #sc-514302), phospho
MAP-ERK 12 (Cell Signaling, Danvers, MA, USA, #5726S), total AKT (Cell Signaling, Danvers, MA, USA,
#9272S), and GAPDH (Cell Signaling, Danvers, MA, USA, #5174S). Secondary antibodies included
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HRP-conjugated mouse-IgGκ (Santa Cruz, CA, USA, #sc-516102) and mouse anti-rabbit IgG-HRP
(Santa Cruz, CA, USA, #sc-2357).
2.9. T-Lymphocyte Functional Studies
For allogeneic Mixed Lymphocyte Reactions (MLRs), human peripheral blood mononuclear cells
were obtained from healthy volunteers via leukapheresis after provision of informed written consent,
and in accordance with the principals of the Declaration of Helsinki and National Institutes of Health
(NIH) guidelines for human subjects, through protocols approved by the Institutional Review Boards
of the Cleveland Clinic (08–957) and Kent State University (18–421), and collected cells were separated
via countercurrent centrifugal elutriation into monocyte-rich and lymphocyte-rich fractions [24].
Co-cultures of allogeneic activated dendritic cells and lymphocytes derived from elutriated cells were
set up as described previously [23] in the presence or absence of 1–10 µM simvastatin, and IFN-γ
assessed in co-culture supernatants 72 h later as described previously [23]. For EliSpot assays, human
Peripheral Blood Mononuclear Cells (PBMCs) were purchased from CTL Corporation (Shaker Heights,
OH, USA) and stimulated in vitro with viral peptide ‘plus’ peptide pool (10 µL/well; CTL corp)
or Tetanus Toxoid (2 µg/mL; Sigma) in the presence or absence of 1–10 µM simvastatin in 96-well IFN-γ
EliSpot assay plates (CTL corp). After 24 h, incubation plates were developed as per manufacturer’s
protocol and analyzed as described previously [23].
2.10. Generation of Mouse Dendritic Cells
Immature DCs were obtained from the bone marrow of female Balb/c mice as previously
described [25]. Briefly, bone marrow was harvested from Balb/c mouse femur and tibia, cultured for
six days in RPMI-1640 media (BioWhittaker, Walkersville, MD, USA) supplemented with 10% v/v
fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA, USA), 100 units/mL of potassium
penicillin and 100 µg/mL of streptomycin sulfate (BioWhittaker), 2 mM L-glutamine (BioWhittaker),
1 mM sodium pyruvate (BioWhittaker), 1% non-essential amino acids (BioWhittaker), 30 ng/mL human
Flt-3L and 25 ng/mL murine IL-6 (both from Peprotech, Rocky Hill, NJ, USA). On day six, cells were
harvested, washed twice in PBS, resuspended in culture media supplemented with 50 ng/mL murine
GM-CSF and 10 ng/mL IL-4 (both from Peprotech), and incubated overnight. The next day, the cells
were harvested then frozen in FBS (2 × 107 cells) containing 10% DMSO (Sigma-Aldrich, St. Louis, MO,
USA). On the day of vaccination, cells were thawed, washed once with PBS to remove DMSO, and then
resuspend in culture media containing only 1% FBS and supplemented with murine GM-CSF and IL-4.
After 1 h of incubation, the cells were exposed to murine HER-2 peptides (two class II peptides and one
class I peptide), incubated for 2 additional hours, activated with 20 ng/mL LPS and 10 ng/mL CpG
(both from Invivogen, San Diego, CA, USA), incubated for 2 more hours, harvested, washed three
times in PBS, then resuspended in PBS at a concentration of 1 × 107 cells/mL for vaccination.
2.11. Therapy Model
2.11.1. Mice
Female Balb/c mice, 10–12 weeks of age, were purchased from Charles River Laboratories
(Wilmington, MA, USA). They were maintained in a specific pathogen-free environment in the animal
facility at Kent State University in accordance with the NIH guidelines. Experiments were approved
by the Institutional Animal Care and Use Committee of Kent State University (protocols 451GK17-15
and 481 GK 19-05).
2.11.2. Tumor Model
The mouse mammary tumor cell line, TUBO (RRID: CVCL_2A33), was a gift from Dr. Wei Zen
Wei of Wayne State University, being originally isolated from a spontaneously arising mammary
tumor in a rat HER-2 transgenic mouse [26]. TUBO cells were cultured in RPMI-1640 media
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supplemented with 10% v/v fetal calf serum (FCS; Atlanta Biologicals, Flowery Branch, GA, USA),
100 units/mL of potassium penicillin and 100 µg/mL of streptomycin sulfate (BioWhittaker), 2 mM
L-glutamine (BioWhittaker), 1 mM sodium pyruvate (BioWhittaker), and 1% non-essential amino acids
(BioWhittaker). Cells were harvested with Cell Dissociation Buffer (Gibco, Grand Island, NY, USA),
washed twice with PBS, and then resuspended in PBS for inoculation.
Thirty Balb/c mice were divided into six groups containing five mice per group. On day zero,
all mice were subcutaneously inoculated with 2.5 × 105 TUBO cells in 100 µL of PBS. At Day 7
post-implantation, when tumors became palpable, mice were either left untreated (control) or treated
with simvastatin (20 mg/kg i.p.); peptide-pulsed DC (1 million DC/treatment/mouse s.q. flanks),
IFN-γ (10 µg/mouse i.p.); DCs plus simvastatin, or IFN-γ plus simvastatin. Peptide-pulsed dendritic
cells were administered twice weekly over the course of three weeks, for a total of six treatments.
Both simvastatin and IFN-γ were given five times per week for three weeks. Calipers were used to
measure the total tumor volume (length multiplied by width) every 2–3 days. Treatment was ceased
on Day 25, but tumors were monitored until Day 30, when in adherence with our protocol, mice were
taken down due to tumor volume.
2.12. Statistical Analysis
Experiments were repeated at least three times with consistent results. Values were processed
using Microsoft Excel 2016 software and are presented as the mean ± standard error of the mean
(SEM). Statistical analyses were performed using one-way ANOVA; p-values < 0.05 were considered
statistically significant. To identify statistical differences between treatment groups following ANOVA,
the Tukey’s Honest Significant Difference (HSD) post-hoc test was used. Statistical analyses were
conducted with SigmaPlot v12.0 statistical software (Systat Software Inc., San Jose, CA, USA).
3. Results
3.1. Th1 Cytokines Work Cooperatively with Statin Drugs to Suppress Metabolic Activity of Breast
Cancer Cells
We examined the effects of Th1 cytokines and statin drugs on four human breast cancer cell lines.
These included SK-BR-3 and the herceptin-resistant HCC1419 as representative HER-2pos cells, and for
comparison, “triple-negative” lines MDA-MB-231 and MDA-MB-468 (Table 1). We restricted our
study to ER-negative lines because previous reports identified the ER-positive phenotype as relatively
insensitive to statins [27]. Initial dose–response studies (Figure 1) established optimized cytokine/drug
concentrations used throughout the study; 10 ng/mL TNF-α, 10 ng/mL IFN-γ, 1 µM simvastatin
or fluvastatin (MDA-MB-231 only), and 10 µM simvastatin or fluvastatin (SK-BR-3, HCC1419,
and MDA-MB-468). Although each cell line showed variable sensitivity to single agents, all four
cell lines showed significantly (p < 0.001) less reduction of alamar blue dye (indicating decreased
metabolism) when treated with statin drugs and Th1 cytokines simultaneously (Figure 2). This was
true for both simvastatin and fluvastatin. Therefore, statin drugs and Th1 cytokines displayed at least
additive effects for suppressing cellular metabolism of breast cancer lines.
3.2. Combined Treatment Leads to Increased Cell Death
For each cell line tested, combined treatment with Th1 cytokines and simvastatin (Figure 3A)
or Th1 cytokines and fluvastatin (Figure 3B) resulted in progressively greater retention of trypan blue
dye (rightward shift in histogram) compared to no treatment or treatment with single agents. Statistical
analysis of cells (Figure 3C) considered “live” or “dead” by virtue of staining intensity revealed
that death induced by combined treatment was significant over single treatments (p-values ranged
from p < 0.001 to p = 0.024 depending on cell line and statin combination). The Th1 cytokine–statin
combinations in these experiments were highly potent, achieving at least 82% cell death and a maximum
of 98%.
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Table 1. Properties of the human breast cancer cell lines subjected to treatment.
SK-BR-3 HCC1419 MDA-MB-231 MDA-MB-468
Subtype [28,29] Luminal Subtype Luminal Subtype Basal B Subtype Basal A Subtype
Source [28] Pleural Effusion Primary Tumor Pleural Effusion Pleural Effusion
Tumor Type [28] Adenocarcinoma Ductal Carcinoma MetastaticAdenocarcinoma
Metastatic
Adenocarcinoma
Estrogen Receptor [28–30] - - - -
Progesterone Receptor [28–30] - - - -
EGFR * [30] +2 - +1 +3
HER-2 * [28–30] +3 +1 - -
HER-3 * [8,29,31] Moderate Moderate/High Low/Absent Moderate
Ras Mutant [32,33] Wild Type Wild Type mut-K Wild Type
* EGFR (Epidermal Growth Factor Receptor), HER-2 (Human Epidermal Growth Factor Receptor-2), HER-3 (Human
Epidermal Growth Factor Receptor-3).
Figure 1. Statin dose–response curves via Alamar Blue dye reduction assay. Human breast cancer cell
lines (SK-BR-3, HCC1419, MDA-MB-231, and MDA-MB-468) were treated with increasing concentrations
of (A) Simvastatin or (B) Fluvastatin in the presence (short dash) or absence (long dash) of recombinant
Th1 cytokines (Tumor Necrosis Factor-alpha, TNF-α and Interferon-gamma, IFN-γ, 10 ng/mL each)
for 72 h. Alamar Blue dye was added and, following color change, the optical density of the dye in
the culture supernatants was determined. Optical Density (OD) values of untreated controls (black)
and cytokine only treatment (gray) are represented as horizontal lines.
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Figure 2. Combination of Th1 cytokines and statin drugs potentiates metabolic suppression in breast
cancer lines. SK-BR-3, HCC1419, MDA-MB-231, and MDA-MB-468 human breast cancer cell lines were
cultured with no additives (No Tx), treated with recombinant Th1 cytokines (“Cyto” TNF-α and IFN-γ,
10 ng/mL each), statin drugs (Simvastatin or Fluvastatin, 1 µM MDA-MB-231; 10 µM remaining cell
lines), or the combination of Th1 cytokines and a statin drug (“Statin + Cyto”). After 72h incubation,
Alamar Blue dye was added and, following color change, optical density of culture supernatants
was determined. Results displayed are from one representative experiment of at least four trials +/−
Standard Error of the Mean (SEM). Letter designations represent Tukey’s Honest Significant Difference
(HSD) comparisons: treatments with the same letter designation are not statistically different; when
letter designations differ between treatments, the p-value is less than 0.05.
Figure 3. Combination of Th1 cytokines and statin drugs maximize cell death in breast cancer lines.
SK-BR-3, HCC1419, MDA-MB-231, and MDA-MB-468 human breast cancer cell lines were cultured
with no additives (No Tx), treated with recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL
each), a statin drug (A) Simvastatin or (B) Fluvastatin (1 µM MDA-MB-231; 10 µM remaining cell
lines), or the combination of Th1 cytokines and a statin drug (A) “Simva + Cyto” or (B) “Fluva +
Cyto”. Flow cytometric results displayed in panels A and B are from one representative experiment.
(C) Graphical interpretation of gated flow cytometric results comparing the percentage of stained events
between groups: no additives (No Tx), treated with recombinant Th1 cytokines (TNFα and IFNγ,
Vaccines 2020, 8, 72 8 of 19
10 ng/mL each), a statin drug (Simvastatin or Fluvastatin, 1 µM MDA-MB-231; 10 µM remaining
cell lines), or the combination of Th1 cytokines and a statin drug (“Statin + Cyto”). Results displayed are
from at least three trials +/− SEM. Letter designations represent Tukey’s HSD comparisons: treatments
with the same letter designation are not statistically different; when letter designations differ between
treatments, the p-value is less than 0.05.
3.3. Combined Treatment Results in Higher Frequency of Apoptotic Cell Death
We next sought to determine whether there was evidence that cell death proceeded through
an apoptotic mechanism. Our criterion contained a set of features associated with apoptosis including
mitochondrial depolarization, characteristic changes in cell membranes, and activation of caspase 3/7.
In the tetramethylrhodamine ethyl ester (TMRE) assay, dying cells cannot sequester the fluorescent
dye in their mitochondria, and so histograms shift left with death (simvastatin, Figure 4A; fluvastatin,
Figure 4B). In three of the four cell lines, significantly less fluorescence was observed when statin
drugs were combined with Th1 cytokines (p-values ranged from p < 0.001 to p = 0.046, depending
on cell line and statin combination) compared with either treatment alone; the exception being
HCC1419, in which no significant difference was observed for dual treatment. For both the HCC1419
and SK-BR-3 cell lines (Figure 4C, top panels), it appears that the Th1 cytokines were responsible
for the bulk of the mitochondrial transmembrane potential loss. The addition of the statin drug had
little to no effect over cytokines alone on the HCC1419 cell line (p ≥ 0.948), but the combination did
cause a statistically significant, yet modest, decrease in mitochondrial transmembrane potential for
the SK-BR-3 cell line (Th1 cytokines with simvastatin, p = 0.011; Th1 cytokines with fluvastatin, p < 0.001).
Treatment with Th1 cytokines had minimal effect on MDA-MB-231 cells (p ≥ 0.929) compared with no
treatment (Figure 4C, bottom left panel). However, this cell line demonstrated strongly diminished
mitochondrial transmembrane potential in response to either statin drug, simvastatin (p = 0.005)
or fluvastatin (p < 0.001). When the statin drugs were combined with Th1 cytokine treatment, there
was nonetheless a significantly enhanced effect (p < 0.001). Treatment of MDA-MB-468 cells with Th1
cytokines (Figure 4C, bottom right panel) caused a statistically significant, yet modest suppression
of mitochondrial transmembrane potential (p < 0.001). Statin treatment alone had a similar effect
(p < 0.001). In contrast, when both treatments were combined, cellular mitochondrial transmembrane
potential was suppressed dramatically (p < 0.001).
Annexin V/PI staining was performed on the second day post-treatment (Figure 5). Dot plot
analysis revealed that for SK-BR-3, MDA-MB-231 and MDA-MB-468, treatment with Th1 cytokines plus
statin drugs (simvastatin Figure 5A; fluvastatin Figure 5B) resulted in greater numbers of double-stained
(i.e., apoptotic) cells compared with single treatments (Figure 5C). For these three lines, these differences
were statistically significant (p-values ranging from p < 0.001 to p = 0.013, depending on line and statin
drug). Only HCC1419 cells did not show enhanced apoptosis with dual treatment by this assay.
The CellEvent™ assay for detection of activated caspases 3 and 7 was also performed on the second
day post-treatment. Here, caspase 3/7 activity in cells undergoing apoptosis alters a cell-permeable
substrate which imparts fluorescence to the cells, shifting the histogram curve to the right. Caspase-3/7
activity was clearly enhanced with dual treatment compared with either Th1 cytokines or statins alone
(simvastatin Figure 6A; fluvastatin Figure 6B).
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Figure 4. Statin drugs plus Th1 cytokines maximize mitochondrial membrane depolarization
as assessed by tetramethylrhodamine ethyl ester (TMRE) staining. SK-BR-3, HCC1419, MDA-MB-231,
and MDA-MB-468 human breast cancer cell lines were cultured with no additives (No Tx), treated with
recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL each), a statin drug (A) Simvastatin or (B)
Fluvastatin (1 µM MDA-MB-231; 10 µM remaining cell lines), or the combination of Th1 cytokines
and a statin drug (A) “Simva + Cyto” or (B) “Fluva + Cyto” for approximately 48 h. Flow cytometric
results displayed in panels A and B are from one representative experiment. (C) Statistical analysis of
flow cytometry results comparing the mean channel fluorescent intensity between groups: no additives
(No Tx), treated with recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL each), a statin drug
(Simvastatin or Fluvastatin, 1 µM MDA-MB-231; 10 µM remaining cell lines), or the combination of Th1
cytokines and a statin drug (“Statin + Cyto”). Results displayed are from at least five trials +/− SEM.
Letter designations represent Tukey’s HSD comparisons: treatments with the same letter designation
are not statistically different; when letter designations differ between treatments, the p-value is less
than 0.05.
3.4. Th1 Cytokines and Statin Drugs Affect K-Ras Membrane Localization and Influence Downstream
Signaling Targets
After 24 h of treatment with statin drugs, Th1 cytokines, or both, the presence of K-Ras in
the membrane and cytosolic fractions of MDA-MB-231 cells was assessed (Figure 7A). As illustrated
in Figure 7B, densitometry analysis showed that K-Ras level in the membrane fraction (black bars)
was the lowest for both simvastatin (upper panel) and fluvastatin (lower panel) when drugs were
combined with Th1 cytokines. Conversely, K-Ras levels in the cytoplasm (gray bars) tended to be
highest with dual treatment. Yet, we detected no evidence of change in the overall levels of K-Ras from
unfractionated cells (Figure 7C,D), suggesting that treatment with cytokines plus drug was causing
a redistribution of K-Ras but not its destruction.
Vaccines 2020, 8, 72 10 of 19
Figure 5. Statin drugs plus Th1 cytokines maximize apoptotic markers in breast cancer lines. SK-BR-3, HCC1419,
MDA-MB-231, and MDA-MB-468 human breast cancer cell lines were cultured with no additives (No Tx),
treated with recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL each), a statin drug (A) Simvastatin
or (B) Fluvastatin (1 µM MDA-MB-231; 10 µM remaining cell lines), or the combination of Th1 cytokines
and a statin drug (A) “Simva + Cyto” or (B) “Fluva + Cyto”. Flow cytometric results displayed in panels
A and B are of one representative experiment from 3 separate trials with each drug. (C) Statistical analysis of
composite results for proportions of double-staining cell events between groups: no additives (No Tx), treated
with recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL each), a statin drug (Simvastatin or Fluvastatin,
1µM MDA-MB-231; 10µM remaining cell lines), or the combination of Th1 cytokines and a statin drug (“Statin +
Cyto”). Results displayed are from three trials +/− SEM. Letter designations represent Tukey’s HSD comparisons:
treatments with the same letter designation are not statistically different; when letter designations differ between
treatments, the p-value is less than 0.05.
Figure 6. Cells treated with a statin drug and Th1 cytokines demonstrate enhanced activation of
caspase 3/7. SK-BR-3, HCC1419, MDA-MB-231, and MDA-MB-468 human breast cancer cell lines were
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cultured with no additives (No Tx), treated with recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL
each), a statin drug (A) Simvastatin or (B) Fluvastatin (1 µM MDA-MB-231; 10 µM remaining cell
lines), or the combination of Th1 cytokines and a statin drug (A) “Simva + Cyto” or (B) “Fluva + Cyto”
and stained with CellEvent™ fluorescent caspase substrate. The experiment was repeated at least three
times; the displayed flow cytometric results are from one representative experiment. The percentage of
stained events, as well as the geometric mean channel fluorescence (in parentheses), is annotated on
each histogram.
Figure 7. Combined treatment with Th1 cytokines and statin drugs potentiates K-Ras delocalization from
membrane. MDA-MB-231 human breast cancer cells were cultured with no additives (No Tx), treated with
recombinant Th1 cytokines (TNF-α and IFN-γ, 10 ng/mL each), a statin drug (Simvastatin or Fluvastatin, 1 µM),
or the combination of Th1 cytokines and a statin drug (“Simva + Cyto” or “Fluva + Cyto”) for 24 h. Membrane
proteins were separated from cytosolic proteins and the distribution of the K-Ras protein was analyzed by
Western blot. (A) Representative Western blot images and (B) corresponding semi-quantitative densitometry
analysis of K-Ras normalized to β-actin loading control. Representative Western blot images of whole-cell K-Ras,
AKT, ERK 12 , and phospho-ERK
1
2 after (C) 24 and (D) 72 h of treatment. Semi-quantitative densitometry analysis
of the (E) GAPDH-normalized total AKT, (F) GAPDH-normalized total ERK-1/2, and (G) GAPDH-normalized
phosphorylated ERK-1/2. All Western blot experiments were repeated at least three times. Displayed graphical
results in panels (E), (F), and (G) are from at least three trials +/− SEM. Letter designations in panel (E) represent
Tukey’s HSD comparisons: treatments with the same letter designation are not statistically different; when letter
designations differ between treatments, the p-value is less than 0.05.
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When no significant changes in the levels of downstream effectors of Ras were seen 24 h
post-treatment (Figure 7C), lysates were examined following 72 h of treatment (Figure 7D). Treatment
with Th1 cytokines alone demonstrated a modest decrease in total AKT (simvastatin series, p = 0.41;
fluvastatin series, p = 0.096); there was a significant decrease in total AKT in response to either statin
drug (simvastatin, p < 0.001; fluvastatin, p = 0.015); and when the statin drugs were combined with Th1
cytokines, the decrease in total AKT was further enhanced (Th1 cytokines with simvastatin, p < 0.001;
Th1 cytokines with fluvastatin, p = 0.005) (Figure 7E). No statistically significant change in the amount
of total ERK was observed (Figure 7F), yet while also not achieving statistical significance (simvastatin
series, p = 0.232; fluvastatin series, p = 0.311), consistent trends were observed including enhanced
phosphorylation with statins alone which were subsequently diminished when combined with Th1
cytokines (Figure 7G).
3.5. Simvastatin Does Not Interfere with T Cell Function and Potentiates Anti-Tumor Activity When Combined
with DC-Based Immunotherapy in a Mouse Model of HER-2pos Breast Cancer
If the intent is to improve immune response rates by using statins in conjunction with
Th1-polarizing vaccine therapy, the drugs must not interfere severely with T cell function—particularly
their ability to produce effector cytokines. Hence, we examined the capacity of healthy donor
lymphocytes to secrete IFN-γ in response to a number of stimuli provided in the presence or absence
of simvastatin. IFN-γ EliSpot analysis of healthy donor Peripheral Blood Mononuclear Cells (PBMCs)
stimulated with a pool of common viral peptide recall antigens (Figure 8A,B, left panels) or tetanus
toxoid (Figure 8A,B, right panels) showed no more than mild simvastatin-induced diminution of
spot-forming cells, which did not reach statistical significance. Likewise, in the allogeneic Mixed
Leukocyte Reaction (MLR) (Figure 8C), IFN-γ levels were only slightly reduced at the highest
concentration of simvastatin (10 µM), and as with the Elispot analysis, the differences were not
statistically significant. We therefore conclude that simvastatin does not severely inhibit the capacity of
T cells to respond to antigen and secrete IFN-γ.
To determine whether the in vitro effects of simvastatin and cytokines could be replicated in
the setting of active therapeutic vaccination, TUBO murine breast carcinoma cells, which overexpress
the rat neu homolog, were implanted into the region of the fat pad of the breast in female Balb/c
mice. Seven days later, when tumors were palpable, tumor-bearing mice were divided into four
groups. The first received no treatment (control). The second received rat HER-2/neu peptide-pulsed
DC immunotherapy twice weekly via subcutaneous flank injection over the course of three weeks.
The third group received three 5-day cycles of simvastatin over the same time period as the DC group.
The final group received both therapies concurrently. Tumor growth was monitored periodically from
the onset of therapy (Figure 8D). It was clear from the growth kinetic curves that single treatments
were virtually superimposable on the untreated group. Only the group treated with both DC-based
immunotherapy and simvastatin showed obvious suppressed growth, and statistical analysis of tumor
sizes on the final day of the study showed dual treatment was significant over all other groups
(dual treatment versus no treatment, p = 0.0007; dual treatment versus simvastatin alone, p = 0.02;
dual treatment versus dendritic cells alone, p = 0.03).
If the DC therapy’s contribution to the anti-tumor activity of dual-treatment therapy occurs
substantially through the induction of Th1 soluble factors, then it should be possible substitute
vaccination with the in vivo administration of recombinant cytokines, and still see the original
therapeutic effect when supplied in combination with simvastatin. To test this hypothesis, we first
confirmed that TUBO cells were sensitized to cytokine-mediated cell death by the presence of
simvastatin (Figure 8E). We treated cultured TUBO cells with either IFN-γ plus TNF-α, or IFN-γ
alone in the presence of increasing concentrations of simvastatin. As concentrations of simvastatin
rose, alamar blue analysis showed a strong leftward shift of the dose–response curve when both Th1
cytokines were present, indicating the drug indeed sensitized TUBO cells to Th1 cytokine-mediated cell
death. When the only cytokine was IFN-γ, there was likewise a leftward shift, albeit not as pronounced.
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Figure 8. Simvastatin does not interfere with T cell function and enhances effects of immunotherapy
in a mouse model of HER-2pos breast cancer. (A) Example IFN-γ EliSpot wells from individual
healthy donor Peripheral Blood Mononuclear Cells (PBMCs) stimulated with a mixture of common
viral peptide recall antigens (left panel) or tetanus toxoid (right panel) in the presence or absence of
simvastatin (“Simva”; 1–10 µM). (B) Composite analysis of each of the 3 donors for viral recall peptides
(left panel) and 3 donors for tetanus toxoid (right panel). Statistical analysis by one-way ANOVA
indicated no significant difference between simvastatin-treated and untreated groups. (C) IFN-γ
ELISA analysis of 72 h culture supernatants from allogeneic Mixed Leukocyte Reactions (MLRs)
where activated dendritic cells (DC) and lymphocyte-rich elutriation fractions were co-cultured at 1:40
stimulator:responder ratios in the presence or absence of 1–10µM simvastatin. Data displayed represents
the mean IFN-γ production from seven unique allogeneic DC:lymphocyte pairings. Statistical analysis
by one-way ANOVA indicated no significant difference between simvastatin-treated and untreated
groups (B.D. = below detection). (D) TUBO-bearing Balb/c mice, 7 days after implantation, were either
left untreated (“No Rx”) or treated with Simvastatin (“Simva”), peptide-pulsed DC-based therapy
(“DC”), or given combined treatment with simvastatin plus peptide-pulsed DCs (“Both”). Tumor size
was measured periodically with calipers during treatment. Tumor size denoted as average area +/− SEM.
Statistical significance is indicated by the asterisk (*). (E) TUBO cells were cultured in vitro with IFN-γ
plus TNF-α, IFN-γ only, or no treatment in the presence of increasing concentrations of Simvastatin for
72 h, then assessed for metabolic activity by the Alamar Blue dye assay. (F) TUBO-bearing Balb/c mice,
7 days after implantation, were either left untreated (“No Rx”) or treated with Simvastatin (“Simva”),
Interferon-γ (“IFN-γ”) or given combined treatment with simvastatin plus IFN-γ (“Both”). Tumor size
was measured periodically with calipers during treatment. Tumor size denoted as average area +/−
SEM. Statistical significance is indicated by the asterisk (*).
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Despite the lower magnitude of anti-tumor activity seen in vitro when IFN-γ was the only Th1
cytokine, for the in vivo study, we chose to omit TNF-α, due to its reputation of unacceptably high
toxicity when administered systemically. For this experiment, we chose a similar experimental design
as before, but instead of DC-based immunotherapy, mice received 10 µg doses of murine recombinant
IFN-γ administered intraperitoneally on the same days they received simvastatin. We found that IFN-γ
alone seemed to slightly retard tumor outgrowth (Figure 8F), but this retardation was not significantly
different from no treatment. In contrast, IFN-γ plus simvastatin significantly suppressed tumor growth
compared with no treatment (p = 0.003), and to a degree highly similar to that seen with DC-based
immunotherapy plus simvastatin (Figure 8D). This study shows that simvastatin enhances vaccine
effects in vivo, and furthermore is consistent with a cytokine-based immune effector mechanism for
combined activity.
4. Discussion
The use of statin drugs is associated with increases in apoptosis and lower recurrence rates in breast
cancer [14,15,19,34]. In addition to breast cancer, epidemiological studies have also suggested anti-cancer
effects of statins in prostate, colorectal, and endometrial cancer. Overall, these observations have
prompted suggestions of clinical trials incorporating statin drugs with current treatment regimens [13].
Such actions are particularly timely, since it is being increasingly recognized that the 10–15 year
development cycle and billion-plus dollar investment required to bring novel drugs to market is
probably unsustainable in the framework of current national and global healthcare [35]. Consequently,
the concepts of “drug repurposing” and “drug repositioning” have been advanced [36]. “Repurposing”
describes a recommended strategy of identifying anti-cancer activity in existing FDA-approved drugs,
not originally developed for treatment of malignancies, to speed deployment and reduce costs of
improved therapies. Similarly, “repositioning” refers to identifying a new setting or context that
derives improved activity from an existing drug. We not only provide justification for the repurposing
and repositioning of simvastatin as an anti-cancer agent, but also suggest this drug as a representative
of a new category of compounds that might be called “biochemical adjuvants”. Whereas traditional
vaccine adjuvants work by enhancing the magnitude or quality of immune responses during the priming
phase, a biochemical adjuvant, as we use this term, does not alter immunity per se, but instead work by
sensitizing the target to the immunotherapy induced effectors of immunity.
Because we have developed a DC-based vaccine that induces strong Th1 immunity in humans,
we began our studies by examining the contributory effects of Th1 cytokines (the primary effectors of
these lymphocytes) and two lipophilic statin drugs on diverse breast cancer lines. We indeed found
that statin drugs work with Th1 cytokines to potentiate apoptosis in breast cancer cells. For most tested
lines, Th1 cytokines and statin drugs each separately contributed substantial activity. The exception
was MDA-MB-231 cells. This line was relatively resistant to effects of Th1 cytokines while showing
more sensitivity to statin drugs alone. Nonetheless, combination of Th1 cytokines with either of two
structurally distinct lipophilic statin drugs consistently and significantly maximized markers of cell
death. Relative statin sensitivity of MDA-MB-231 is probably explained by constitutively activated Ras,
and has been reported previously [27]. Consequently, this line is probably more dependent (oncogene
addiction) on Ras signaling than the other tested lines.
There were two unexpected findings. The first was that Th1 cytokines and statin drugs worked
cooperatively to delocalize K-Ras from the membrane fraction and into the cytoplasm. The second
was the increased phosphorylation of ERK in statin-treated cells. Though constitutively activated in
MDA-MB-231 cells, Ras must still localize in the plasma membrane to function [17,18,37]. Membrane
association is obtained in two ways: through a lipid adduct (such as farnesylation), synthesis of which is
dependent upon activity of the mevalonate pathway, and also through the second signal located in
the linker domain of the protein’s C-terminal hypervariable region (in the case of K-Ras, a polybasic
domain, which interacts with inner-leaflet phosphatidylserine residues) [38,39]. However, since ERK
phosphorylation is associated with K-Ras activity, why does statin treatment increase downstream
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ERK phosphorylation rather than decrease it, and how can Th1 cytokines contribute to statin-induced
Ras displacement?
To explain these observations, it is important to note that the inhibition of the mevalonate pathway
by statins inhibits cholesterol synthesis, thus lowering membrane cholesterol content [40]. Cholesterol
is critical for maintaining microdomain structures known as caveolae, which sequester membrane
lipids, including phosphatidylserine. In fact, phosphatidylserine sequestration by caveolae leaves
less than 40% of inner-leaflet phosphatidylserine available for interaction with signaling molecules
such as Ras. Loss of membrane cholesterol would disrupt caveolae and allow redistribution of
phosphatidylserine in the inner leaflet membrane, promoting K-Ras nanoclustering and the formation
of effective signaling complexes leading to downstream phosphorylation of ERK [18,41–43]. So, even if
statin drugs inhibit localization of Ras to the membrane, any of the molecules already in the membrane
could likely signal more efficiently, accounting for the higher levels of ERK phosphorylation seen with
statin treatment alone.
As for the role of Th1 cytokines in enhancing K-Ras delocalization from the membrane fraction,
the cytokines IFN-γ and TNF-α have been shown by others to affect lipid metabolism and membrane
composition. More specifically, the cytokines have been shown to increase the presence of saturated
fatty acyl groups on membrane components, while decreasing unsaturated fatty acyl groups, leading to
overall lowered membrane fluidity [44,45]. Significantly, K-Ras has been shown to optimally
associate with membranes when the bilayer is more loosely packed (i.e., more unsaturated fatty
acyl groups) [46,47]. Consequently, Th1 cytokines would be expected to induce membrane properties
less favorable for Ras association. In addition, we show that the Th1 cytokines, as a consequence of
apoptosis induction, cause the appearance of phosphatidylserine on the outer leaflet of the plasma
membrane (these are presumably flipped from the inner leaflet during apoptosis). Therefore, yet
another important anchoring molecule for Ras is diminished in cells treated with both statins and Th1
cytokines. Fully testing this proposed mechanism will require a detailed study of changes in membrane
composition and biophysical properties induced by combinations of statin drugs and Th1 cytokines.
Because the PI3K/PBK/AKT intracellular signaling pathway also lies downstream of Ras,
and promotes aspects of cell growth, survival, motility and resistance to apoptosis [48], we initially
anticipated seeing attenuated phosphorylation in members of this pathway, owing to presumed losses
in upstream Ras activity. Instead, we observed a trend toward loss of total AKT expression evident by
72 h post-treatment (Figure 7D,E). This is perhaps not surprising given that we had previously reported
selective loss of HER-family receptors in multiple breast cancer lines undergoing Th1 cytokine-induced
apoptosis [8]. It is likely that the expression of multiple components of growth factor signaling
pathways are particularly sensitive to negative regulation during apoptosis as a means of limiting
conflicting growth/death signals as apoptosis proceeds.
Perhaps of greatest interest was our demonstration that simvastatin combined with
an IL-12-secreting DC-based therapy significantly retarded tumor growth kinetics while single
treatments did not. We predicted this would be the case, since both Th1 immunity and statin use has
been associated with better outcomes for breast cancer [49,50]. Even a single parenterally supplied Th1
cytokine (IFN-γ) showed substantial increased activity in combination with simvastatin in the mouse
model (Figure 8F), consistent with the notion that Th1 cytokines are major effector mechanisms of
DC immunotherapy induced responses in this model, and furthermore suggesting a non-cell-based
immunotherapy (i.e., a recombinant cytokine) that can be used in combination with simvastatin to
achieve an anti-tumor effect. It is tempting to speculate that the subset of breast cancer patients who
benefit from statins may be those who already have substantial associated anti-tumor Th1 immunity,
insufficient to provide protection on its own, but adequate to suppress cancer recurrence when combined
with the drug. It should be noted that the mouse model used in these studies, as a proof-of-principle,
involved providing treatment in the setting of a progressively growing tumor, and the immunotherapy
(as constituted in the study) in combination with statin drugs, though substantially slowing tumor
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growth, was not actually curative. This model may, however, supply a basis for optimization that may
achieve improvements in therapeutic activity.
5. Conclusions
Th1 cytokines, when combined with lipophilic statin drugs, enhance cell death in cultured HER-2pos
and triple-negative breast cancer lines through an apparent apoptotic mechanism. This treatment
combination also led to maximized delocalization of the K-Ras oncodriver from the plasma membrane
and into the cytoplasm by 24 h exposure, as well as a general loss of AKT expression by 72 h—both
consequences consistent with losses in cell viability. HER-2 pulsed dendritic cells, as well as recombinant
IFN-γ, when combined with statins, suppressed the outgrowth of tumors in a murine model of HER-2pos
breast cancer. These findings provide justification for trials with combinations of immunotherapies
promoting strong Th1 immunity, such as a Th1-polarizing DC vaccine, with well-tolerated statin
drugs to improve outcomes in breast cancer. Possible test settings include treatment after surgical
resection of disease to prevent recurrence, as well as neoadjuvant treatment of high-risk HER-2pos
DCIS patients to minimize chances of recurrence, invasion, and metastasis. Combining select low-cost,
low-risk targeted drugs with immunotherapies to improve efficacy is a promising strategy that probably
warrants further investigation.
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